Bioorganic and Medicinal Chemistry Letters p. 3029 - 3034 (1996)
Update date:2022-07-29
Topics:
Veenstra, Siem J.
Hauser, Kathleen
Schilling, Walter
Betschart, Claudia
Ofner, Silvio
CGP 49823 is a potent NK1 antagonist which is centrally active after oral administration. The SAR of the C-2 substituent was investigated with respect to the affinity to the NK1 receptor. A practical synthesis of CGP 49823, suitable for scale-up, was developed. The key-step, a tandem acyliminium ion cyclization/Ritter reaction, gave trans-2-benzyl-4-acetamido-piperidines with high diastereoselectivity.
View MoreContact:0086-22-2822 1962 / 2822 1963
Address:B-808, No. 1, North-South Street, Hexi District,
Contact:+86-571-86491666
Address:SHI XIANG ROAD
ShangHai Ruiyi Medical Technology Co.,Ltd.
Contact:+86-21-54718086
Address:No951 Jianchuan RD，Minhang District
Zhuhai Rundu Pharmaceutical co.,Ltd
Contact:+86-756-7630755
Address:No.6,North Airport Road,Sanzao Town,Jinwan District
Beijing Mesochem Technology Co.,LTD
website:http://www.mesochem.com
Contact:0086-10-57862036
Address:2301, Floor 23, Building 9 Lippo Plaza, Yard 8 Ronghua Middle Road, ETDZ, Beijing, China
Doi:10.1021/jo961781i
(1997)Doi:10.1016/S0960-894X(97)00008-5
(1997)Doi:10.1002/jhet.5570330626
(1996)Doi:10.1021/ja01077a028
(1964)Doi:10.1248/cpb.45.53
(1997)Doi:10.1021/ja01101a038
(1953)
